Table 3.

Cumulative incidence of second primary malignancies (SPMs) in patients with chronic lymphocytic leukemia (cll) stratified by study periods

	1973–1982	1983–1992	1993–2002	2003–2015
All sites
12-months follow-up	1.2 (0.9–1.5)	0.8 (0.6–1.0)	0.8 (0.6–1.0)	0.9 (0.8–1.0)
60-months follow-up	6.6 (5.8–7.2)	5.5 (4.9–6.0)	5.1 (4.6–5.5)	7.1 (6.6–7.6)
120-months follow-up	11.1 (10.3–11.9)	10.8 (10.2–11.5)	10.1 (9.5–10.8)	19.5 (18.5–20.5)
All solid tumors
12-months follow-up	1.2 (0.9–1.5)	0.8 (0.6–1)	0.8 (0.6–1)	0.7 (0.6–0.8)
60-months follow-up	6.1 (5.4–6.7)	5.1 (4.6–5.6)	4.7 (4.3–5.2)	5.7 (5.3–6.1)
120-months follow-up	10.3 (9.5–11.1)	10.1 (9.5–10.8)	9.1 (8.6–9.8)	15.9 (15–16.7)
All lymphatic and hematopoietic diseases
12-months follow-up	0.05 (0.02–0.2)	0.04 (0.01–0.1)	0.05 (0.02–0.1)	0.2 (0.1–0.3)
60-months follow-up	0.5 (0.3–0.7)	0.4 (0.3–0.5)	0.4 (0.2–0.5)	1.4 (1.2–1.7)
120-months follow-up	0.8 (0.6–1.1)	0.7 (0.5–0.9)	1.0 (0.8–1.3)	3.6 (3.2–4.1)